BR112012005896A2 - composição farmacêutica, combinação farmacêutica, embalagem comercial, usos de agente antitumoral e de derivado de ácido graxo para tratar tumor - Google Patents

composição farmacêutica, combinação farmacêutica, embalagem comercial, usos de agente antitumoral e de derivado de ácido graxo para tratar tumor

Info

Publication number
BR112012005896A2
BR112012005896A2 BR112012005896A BR112012005896A BR112012005896A2 BR 112012005896 A2 BR112012005896 A2 BR 112012005896A2 BR 112012005896 A BR112012005896 A BR 112012005896A BR 112012005896 A BR112012005896 A BR 112012005896A BR 112012005896 A2 BR112012005896 A2 BR 112012005896A2
Authority
BR
Brazil
Prior art keywords
fatty acid
acid derivative
antitumor agent
pharmaceutical composition
commercial packaging
Prior art date
Application number
BR112012005896A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR112012005896A2 publication Critical patent/BR112012005896A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012005896A 2009-09-16 2010-09-16 composição farmacêutica, combinação farmacêutica, embalagem comercial, usos de agente antitumoral e de derivado de ácido graxo para tratar tumor BR112012005896A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24301909P 2009-09-16 2009-09-16
PCT/JP2010/066619 WO2011034210A1 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Publications (1)

Publication Number Publication Date
BR112012005896A2 true BR112012005896A2 (pt) 2016-03-15

Family

ID=43730802

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005896A BR112012005896A2 (pt) 2009-09-16 2010-09-16 composição farmacêutica, combinação farmacêutica, embalagem comercial, usos de agente antitumoral e de derivado de ácido graxo para tratar tumor

Country Status (17)

Country Link
US (3) US9084815B2 (pt)
EP (1) EP2477632A4 (pt)
JP (2) JP5891168B2 (pt)
KR (1) KR101760963B1 (pt)
CN (2) CN107050458A (pt)
AR (1) AR078182A1 (pt)
AU (1) AU2010296307B2 (pt)
BR (1) BR112012005896A2 (pt)
CA (1) CA2772314A1 (pt)
IL (1) IL218392A (pt)
MX (1) MX2012003188A (pt)
NZ (1) NZ598618A (pt)
RU (2) RU2016103415A (pt)
SG (2) SG10201405467PA (pt)
TW (1) TWI535436B (pt)
WO (1) WO2011034210A1 (pt)
ZA (1) ZA201201894B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
JP7176146B1 (ja) 2022-06-15 2022-11-21 山崎 明美 水路用流向計

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
DK0454429T3 (da) 1990-04-27 1997-03-17 R Tech Ueno Ltd Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
JPH0770054A (ja) 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6242485B1 (en) * 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
TWI284535B (en) 2000-03-24 2007-08-01 Sucampo Ag Apoptosis inhibitor
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
RU2440338C2 (ru) 2005-01-27 2012-01-20 Сукампо Аг Способ и композиция для лечения заболеваний центральной нервной системы
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Also Published As

Publication number Publication date
SG179153A1 (en) 2012-04-27
CN102481302A (zh) 2012-05-30
AU2010296307A1 (en) 2012-04-05
RU2012114771A (ru) 2013-10-27
EP2477632A1 (en) 2012-07-25
CN107050458A (zh) 2017-08-18
EP2477632A4 (en) 2013-06-12
US20110064748A1 (en) 2011-03-17
SG10201405467PA (en) 2014-10-30
KR20120081139A (ko) 2012-07-18
TW201116277A (en) 2011-05-16
RU2577700C2 (ru) 2016-03-20
KR101760963B1 (ko) 2017-07-24
JP2013504520A (ja) 2013-02-07
US20170079986A1 (en) 2017-03-23
CA2772314A1 (en) 2011-03-24
MX2012003188A (es) 2012-04-30
JP2016056191A (ja) 2016-04-21
AR078182A1 (es) 2011-10-19
IL218392A (en) 2016-05-31
TWI535436B (zh) 2016-06-01
US9084815B2 (en) 2015-07-21
IL218392A0 (en) 2012-04-30
JP5891168B2 (ja) 2016-03-22
WO2011034210A1 (en) 2011-03-24
NZ598618A (en) 2014-10-31
RU2016103415A (ru) 2018-11-22
ZA201201894B (en) 2012-11-28
AU2010296307B2 (en) 2016-02-11
US20150272961A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
ZA201502840B (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
CL2014001648A1 (es) Composicion farmacéutica que comprende variantes de receptores de polipeptidos de activina y sus usos para tratar cancer.
IN2014MN00948A (pt)
GB2502029B (en) Cosmetic or pharmaceutical formulation comprising hyaluronate crosspolymer and one or more of; azelaic acid, or derivative, and natural oils
IN2014MN02049A (pt)
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BR112013033072A2 (pt) agente para indução de apoptose e composição farmacêutica
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2514415A4 (en) TRANSDERMALLY ABSORBED PREPARATION OF ANTI-DEMENTIA MEDICINE
ITTO20110631A1 (it) Composizione farmaceutica di combinazione e metodi per trattare patologie del sistema genitourinario
BR112015002528A2 (pt) combinação de inibidor de pi3k e inibidor de c-met, seus usos, composição farmacêutica e embalagem comercial
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
ES2661048T8 (es) Composición cosmética de líquido de eclosión de peces, métodos para su producción y usos de la misma para mejorar la apariencia cosmética de la piel
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
GB0916573D0 (en) Composition for treatment of wounds and burns comprising bee-venom as active
BR112012005896A2 (pt) composição farmacêutica, combinação farmacêutica, embalagem comercial, usos de agente antitumoral e de derivado de ácido graxo para tratar tumor
IL217519A (en) Derivatives of tazarotene, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of skin diseases
ZA201408057B (en) Compositions and methods for the treatment of moderate to severe pain
BR112012029747A2 (pt) composição de tratamento da pele, método para fornecer um efeito antimicrobiano para a pele e utilização de uma composição
IL200753A (en) Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
BR112013009647A2 (pt) derivado de vitamina, composição farmacêutica, agente terapêutico, e, composto
EP2716758A4 (en) OLIGONUCLEOTIDE DERIVATIVE, THERAPEUTICALLY ACTIVE PHARMACEUTICAL COMPOSITION, AND DIAGNOSTIC PHARMACEUTICAL COMPOSITION CONTAINING OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE DERIVATIVE FOR REGULATION OF MIRIK ACTIVITY

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.